109 results
6-K
ASND
Ascendis Pharma A/S
2 May 24
Current report (foreign)
4:29pm
at a point in time, where the licensee is granted access to the IP.
Development and regulatory milestones of up to $175 million are recognized as revenue when … assets or liabilities that the entity can access at the measurement date;
Level 2 is based on valuation techniques for which the lowest level input
6-K
EX-99.1
ASND
Ascendis Pharma A/S
2 May 24
Ascendis Pharma Reports First Quarter 2024 Financial Results
4:22pm
at 4:30 pm Eastern Time (ET) to discuss its first quarter 2024 financial results.
Page 3 of 7
Those who would like to participate may access the live
6-K
EX-99.2
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
in the ongoing 3-year extension portion of the PaTHway Japan Trial.
Financial Statements
In December 2022, the FDA allowed us to initiate a U.S. expanded access … for enrollment, allowing U.S. physicians to request access to investigational TransCon PTH for their eligible patients.
In September 2022, we announced new Week
6-K
EX-99.3
ASND
Ascendis Pharma A/S
2 May 24
Notice to convene Annual General Meeting 2024
4:02pm
of physician sites and patients with hypoparathyroidism for the US Expanded Access Program for TransCon PTH. Launched Skytrofa registries in the United … . Vision & Values Patients Clinical Trial Safety Product Safety Patient & Caregiver Access to Medicine Grants & Donations & Diversity & Quality
S-8
EX-99.2
ASND
Ascendis Pharma A/S
29 Feb 24
Registration of securities for employees
4:29pm
accomplishment as a vesting percentage ranging from 0% to 100% of the tranche.
the Participant has opened and maintained access to a specific purpose brokerage … .
It is a precondition for vesting according to clause 4.2 and for the Company’s transfer of ADSs to the Participant that the Participant has access
6-K
EX-99.1
j324tf5 0w0x81rib4s
7 Feb 24
Ascendis Pharma Reports Fourth Quarter and Full Year 2023 Results
4:05pm
6-K
EX-99.1
pczdu668 d48dyq
8 Jan 24
Current report (foreign)
6:08am
6-K
iropxf
7 Nov 23
Current report (foreign)
4:03pm
6-K
mpl9im
5 Sep 23
Current report (foreign)
4:14pm
6-K
EX-99.1
tqfygenmzaj okjd
5 Sep 23
Ascendis Pharma Reports Second Quarter 2023 Financial Results
4:09pm
6-K
EX-99.2
jjxew 5raxkj
2 May 23
Notice to convene Annual General Meeting 2023
4:02pm
6-K
EX-99.3
91zvs6121o
2 May 23
Notice to convene Annual General Meeting 2023
4:02pm
6-K
8aqhfo3o
1 May 23
Current report (foreign)
8:30am
6-K
rq9bw
27 Apr 23
Current report (foreign)
4:02pm
6-K
EX-99.1
23fyh9
27 Apr 23
Ascendis Pharma Reports First Quarter 2023 Financial Results
4:01pm
6-K
updy 5l252ozue8lx
3 Apr 23
Current report (foreign)
8:02am
6-K
5buk5w4ak2zqu899kj
5 Dec 22
Current report (foreign)
8:06am